Sign in or Register   Sign in or Register
  |  

Mouse Anti-SUFU Recombinant Antibody (CBXS-2695) (CBMAB-S5447-CQ)

This product is a mouse antibody that recognizes SUFU. The antibody CBXS-2695 can be used for immunoassay techniques such as: ELISA.
See all SUFU antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBXS-2695
Antibody Isotype
IgG2a, κ
Application
ELISA

Basic Information

Immunogen
Partial recombinant corresponding to aaa181-280, from human SUFU (AAH13291, 51684) with GST tag
Specificity
Human
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.2
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
suppressor of fused homolog (Drosophila)
Introduction
The Hedgehog signaling pathway plays an important role in early human development. The pathway is a signaling cascade that plays a role in pattern formation and cellular proliferation during development. This gene encodes a negative regulator of the hedgehog signaling pathway. Defects in this gene are a cause of medulloblastoma. Alternative splicing results in multiple transcript variants.
Entrez Gene ID
51684
UniProt ID
Q9UMX1
Alternative Names
SUFUH; SUFUXL; PRO1280
Function
Negative regulator in the hedgehog/smoothened signaling pathway (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:12068298, PubMed:12975309, PubMed:27234298, PubMed:15367681, PubMed:22365972, PubMed:24217340, PubMed:24311597, PubMed:28965847).
Down-regulates GLI1-mediated transactivation of target genes (PubMed:15367681, PubMed:24217340, PubMed:24311597).
Down-regulates GLI2-mediated transactivation of target genes (PubMed:24311597, PubMed:24217340).
Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340).
Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:24217340).
Negative regulator of beta-catenin signaling (By similarity).
Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full-length form of GLI3 (GLI3FL) (PubMed:24311597, PubMed:28965847).
GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state (PubMed:24311597, PubMed:28965847).
Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R (PubMed:24311597, PubMed:28965847).
When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A) (PubMed:24311597, PubMed:28965847).
Required for normal embryonic development (By similarity).
Required for the proper formation of hair follicles and the control of epidermal differentiation (By similarity).
Biological Process
Biological Process aorta developmentIEA:Ensembl
Biological Process coronary vasculature developmentIEA:Ensembl
Biological Process cytoplasmic sequestering of transcription factorManual Assertion Based On ExperimentIBA:GO_Central
Biological Process heart loopingIEA:Ensembl
Biological Process negative regulation of DNA-binding transcription factor activityManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of hh target transcription factor activityManual Assertion Based On ExperimentIDA:ComplexPortal
Biological Process negative regulation of osteoblast differentiationManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of protein import into nucleusManual Assertion Based On ExperimentTAS:BHF-UCL
Biological Process negative regulation of smoothened signaling pathwayManual Assertion Based On ExperimentIMP:UniProtKB
Biological Process negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterningIEA:Ensembl
Biological Process negative regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIDA:MGI
Biological Process negative regulation of ubiquitin-dependent protein catabolic processIEA:Ensembl
Biological Process neural tube closureIEA:Ensembl
Biological Process regulation of DNA-templated transcriptionManual Assertion Based On ExperimentTAS:UniProtKB
Biological Process signal transductionManual Assertion Based On ExperimentTAS:ProtInc
Biological Process skin developmentIEA:Ensembl
Biological Process smoothened signaling pathway involved in dorsal/ventral neural tube patterningIEA:Ensembl
Biological Process smoothened signaling pathway involved in spinal cord motor neuron cell fate specificationIEA:Ensembl
Biological Process smoothened signaling pathway involved in ventral spinal cord interneuron specificationIEA:Ensembl
Biological Process ventricular septum developmentIEA:Ensembl
Cellular Location
Cytoplasm
Nucleus
Involvement in disease
Medulloblastoma (MDB):
Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.
Joubert syndrome 32 (JBTS32):
A form of Joubert syndrome, a disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis, and polydactyly. JBTS32 inheritance is autosomal recessive.
Basal cell nevus syndrome (BCNS):
An autosomal dominant disease characterized by nevoid basal cell carcinomas and developmental abnormalities such as rib and craniofacial alterations, polydactyly, syndactyly, and spina bifida. In addition, the patients suffer from a multitude of tumors like basal cell carcinomas, fibromas of the ovaries and heart, cysts of the skin, jaws and mesentery, as well as medulloblastomas and meningiomas.
PTM
Polyubiquitinated at Lys-257 by the SCF(FBXL17) complex, leading to its subsequent degradation and allowing the release of GLI1 for proper hedgehog/smoothened signal transduction (PubMed:27234298).
Ubiquitination is impaired by phosphorylation at Ser-342, Ser-346, Ser-352 and Thr-353 (PubMed:27234298).
Phosphorylation at Ser-342, Ser-346, Ser-352 and Thr-353 prevents ubiquitination by the SCF(FBXL17) complex.
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-SUFU Recombinant Antibody (CBXS-2695)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare